Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedJun 02, 2025
DataAggregated Company Financials
Companies568
- 7D0.1%
- 3M-8.6%
- 1Y-13.1%
- YTD-6.0%
The Biotech is pretty flat in the last 7 days, but Amgen has stood out, gaining 6.1%. Unfortunately though, the industry is down 13% over the past 12 months. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 02 Jun 2025 | US$908.2b | US$155.9b | -US$23,672,769,787.04 | 15.6x | -38.4x | 5.8x |
| Wed, 30 Apr 2025 | US$795.9b | US$119.3b | -US$30,922,989,483.00 | 20.4x | -25.7x | 6.7x |
| Fri, 28 Mar 2025 | US$816.7b | US$118.6b | -US$37,006,972,359.43 | 22.1x | -22.1x | 6.9x |
| Sun, 23 Feb 2025 | US$863.3b | US$117.3b | -US$37,606,528,073.37 | 17x | -23x | 7.4x |
| Tue, 21 Jan 2025 | US$947.4b | US$149.4b | -US$26,290,369,541.36 | 17.3x | -36x | 6.3x |
| Thu, 19 Dec 2024 | US$1.0t | US$149.9b | -US$26,462,738,539.24 | 15.4x | -37.8x | 6.7x |
| Sat, 16 Nov 2024 | US$1.0t | US$150.0b | -US$26,800,374,726.08 | 16x | -38.7x | 6.9x |
| Mon, 14 Oct 2024 | US$902.0b | US$113.1b | -US$36,040,263,614.54 | 20.6x | -25x | 8x |
| Wed, 11 Sep 2024 | US$894.1b | US$113.1b | -US$35,660,564,622.32 | 22.3x | -25.1x | 7.9x |
| Fri, 09 Aug 2024 | US$1.2t | US$166.7b | -US$32,150,549,450.80 | 23.9x | -36.2x | 7x |
| Sun, 07 Jul 2024 | US$1.1t | US$164.5b | -US$28,073,537,735.64 | 27.9x | -40.3x | 6.9x |
| Tue, 04 Jun 2024 | US$1.1t | US$164.6b | -US$26,680,256,870.37 | 27.7x | -42.1x | 6.8x |
| Thu, 02 May 2024 | US$1.1t | US$165.0b | -US$26,426,226,136.78 | 23.2x | -41x | 6.6x |
| Sat, 30 Mar 2024 | US$1.2t | US$164.4b | -US$23,362,713,195.15 | 20.8x | -50.5x | 7.2x |
| Mon, 26 Feb 2024 | US$1.2t | US$166.6b | -US$21,694,939,476.21 | 10.8x | -54.3x | 7.1x |
| Wed, 24 Jan 2024 | US$1.4t | US$204.7b | -US$22,529,001,992.00 | 18.1x | -63.5x | 7x |
| Fri, 22 Dec 2023 | US$1.3t | US$204.8b | -US$22,148,191,573.00 | 19x | -60x | 6.5x |
| Sun, 19 Nov 2023 | US$1.2t | US$204.7b | -US$22,079,556,420.00 | 18.1x | -54.7x | 5.9x |
| Tue, 17 Oct 2023 | US$1.3t | US$207.4b | -US$13,067,799,538.00 | 17.3x | -97.1x | 6.1x |
| Thu, 14 Sep 2023 | US$1.3t | US$207.5b | -US$12,611,945,630.00 | 17.6x | -101.4x | 6.2x |
| Sat, 12 Aug 2023 | US$1.3t | US$207.7b | -US$12,540,100,481.00 | 17.1x | -102.7x | 6.2x |
| Mon, 10 Jul 2023 | US$1.1t | US$186.3b | -US$16,022,507,026.00 | 12.9x | -69.1x | 5.9x |
| Wed, 07 Jun 2023 | US$1.1t | US$185.9b | -US$16,017,335,337.00 | 11.6x | -71.1x | 6.1x |
| Fri, 05 May 2023 | US$1.2t | US$193.7b | -US$11,169,713,239.00 | 14.5x | -103.6x | 6x |
| Sun, 02 Apr 2023 | US$1.2t | US$217.0b | -US$5,990,852,997.00 | 14.3x | -193.4x | 5.3x |
| Tue, 28 Feb 2023 | US$1.1t | US$199.8b | -US$4,402,706,584.00 | 14.3x | -256.6x | 5.7x |
| Thu, 26 Jan 2023 | US$1.2t | US$203.9b | US$1.8b | 14.7x | 652x | 5.7x |
| Sat, 24 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.5x | 703.1x | 5.7x |
| Mon, 21 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.7x | 887.8x | 5.6x |
| Wed, 19 Oct 2022 | US$1.1t | US$206.2b | US$5.5b | 15.8x | 195.6x | 5.2x |
| Fri, 16 Sep 2022 | US$1.1t | US$206.6b | US$5.7b | 15x | 187.8x | 5.2x |
| Sun, 14 Aug 2022 | US$1.1t | US$206.8b | US$7.2b | 15.9x | 155.3x | 5.4x |
| Tue, 12 Jul 2022 | US$1.1t | US$211.3b | US$10.7b | 16.8x | 101.6x | 5.1x |
| Thu, 09 Jun 2022 | US$1.0t | US$212.7b | US$11.3b | 16.6x | 90.2x | 4.8x |
Price to Earnings Ratio
90.2x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.70% | |
| Healthcare | 1.83% | |
| Biotech | 0.13% | |
| Biotech | 0.13% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AMGN Amgen | US$288.18 | 6.1% +US$8.9b | -6.3% | PE26.1x | |
| ABBV AbbVie | US$186.11 | 1.6% +US$5.0b | 16.2% | PE79.1x | |
| GILD Gilead Sciences | US$110.08 | 2.5% +US$3.4b | 73.5% | PE23x | |
| ALNY Alnylam Pharmaceuticals | US$304.56 | 5.0% +US$1.9b | 102.4% | PS16.9x | |
| VRTX Vertex Pharmaceuticals | US$442.05 | 1.4% +US$1.6b | -6.0% | PS10.2x |
